Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience.
Joharatnam-Hogan N, Hochhauser D, Shiu KK, Rush H, Crolley V, Wilson W, Sharma A, Muhammad A, Anwar M, Vasdev N, Goldstein R, Kantser G, Saha A, Raja F, Bridgewater J, Khan K. Joharatnam-Hogan N, et al. Among authors: wilson w. Ther Adv Med Oncol. 2020 Sep 14;12:1758835920956803. doi: 10.1177/1758835920956803. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32968429 Free PMC article.
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.
Crolley VE, Hanna D, Joharatnam-Hogan N, Chopra N, Bamac E, Desai M, Lam YC, Dipro S, Kanani R, Benson J, Wilson W, Fox TA, Shiu KK, Forster M, Bridgewater J, Hochhauser D, Khan K. Crolley VE, et al. Among authors: wilson w. Ther Adv Med Oncol. 2020 Oct 23;12:1758835920971147. doi: 10.1177/1758835920971147. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33178336 Free PMC article.
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA, Wilson W, Kirkwood AA, Wolf J, Hildyard C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Kothari J, Fox CP, Martinez-Calle N, McMillan A, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: wilson w. Blood Adv. 2021 Apr 27;5(8):2229-2236. doi: 10.1182/bloodadvances.2021004286. Blood Adv. 2021. PMID: 33890978 Free PMC article.
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.
Lecat CSY, Taube JB, Wilson W, Carmichael J, Parrish C, Wallis G, Kyriakou C, Lee L, Mahmood S, Papanikolaou X, Rabin NK, Sive J, Wechalekar AD, Yong K, Cook G, Popat R. Lecat CSY, et al. Among authors: wilson w. Front Oncol. 2021 Jul 21;11:703233. doi: 10.3389/fonc.2021.703233. eCollection 2021. Front Oncol. 2021. PMID: 34367987 Free PMC article.
Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experience.
Melotti D, Asher S, Troy-Barnes E, Nesr G, Wilson W, Camilleri M, Popat R, Xu K, Rabin N, Sive J, Papanikolaou X, Lee L, McMillan A, Yong K, Kyriakou C. Melotti D, et al. Among authors: wilson w. EJHaem. 2024 Aug 19;5(5):1102-1106. doi: 10.1002/jha2.977. eCollection 2024 Oct. EJHaem. 2024. PMID: 39415903 Free PMC article.
Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.
Richards H, Chavda SJ, Wilson W, Camilleri M, Cohen O, Horder J, Newrick F, Papanikolaou X, Sive J, Lee L, Popat R, Wechalekar A, Kyriakou C, Yong K, Rabin N. Richards H, et al. Among authors: wilson w. Leuk Lymphoma. 2021 Dec;62(14):3544-3547. doi: 10.1080/10428194.2021.1961240. Epub 2021 Aug 4. Leuk Lymphoma. 2021. PMID: 34348069 No abstract available.
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R. Yong K, et al. Among authors: wilson w. Lancet Haematol. 2023 Feb;10(2):e93-e106. doi: 10.1016/S2352-3026(22)00350-7. Epub 2022 Dec 15. Lancet Haematol. 2023. PMID: 36529145 Free article. Clinical Trial.
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
Michael A, Wilson W, Sunshine S, Annels N, Harrop R, Blount D, Pandha H, Lord R, Ngai Y, Nicum S, Stylianou L, Gwyther S, McNeish IA, Hackshaw A, Ledermann J. Michael A, et al. Among authors: wilson w. Int J Gynecol Cancer. 2024 Aug 5;34(8):1225-1231. doi: 10.1136/ijgc-2023-005200. Int J Gynecol Cancer. 2024. PMID: 38760075 Clinical Trial.
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend W. Northend M, et al. Among authors: wilson w. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953. Blood Adv. 2022. PMID: 35020818 Free PMC article. No abstract available.
4,397 results